Even as the Association of the Pharmacy Teachers of India is persistent on the implementation of a common pharmacist registration process at the national level, the pharmacy professionals in Karnataka highlight on the requirement of One Nation -One Registration benefits. Prof R Raveendra, charter president, Indian Pharmaceutical Association, Peenya Branch, Bengaluru and professor, Department of Pharmaceutical Chemistry, Cauvery College of Pharmacy, Mysuru said the One Nation-One Ration card facility has helped every Indian to get their ration even after migration to other states due to employment and other reasons. In a similar way, the registered pharmacist has to get the right opportunity to work anywhere in India. Once they register their name as registered pharmacist in any State Pharmacy Council the recognition of this status should be automatic. The government and PCI already initiated the process of linking Aadhar card to registered pharmacist of any state pharmacy councils across India, this would give a further impetus to the whole process of One Nation-One Registration. Those who get the opportunity to work in different parts of India in pharmaceutical industry, research departments or community health services, Pharmacovigilance, or even in the academia, their expertise will only be an advantage to the sector, he added. In this regard, PCI should take immediate steps to frame a common guideline to all State Pharmacy Councils to ensure that all State Pharmacy Councils have to follow the same guidelines while registering as pharmacist. Another important aspect is the need to ensure life time registration to each and every registered pharmacist. Karnataka State Pharmacy Council has initiated a unique registration scheme along with social security insurance and health scheme. The One Nation-One Pharmacist registration can allow such initiatives too of pharmacist welfare, said Prof. Raveendra. Also each State Pharmacy Council should appoint senior teachers as pharmacy inspector as per Pharmacy Act to ensure that all pharmacy shops are functioning   under the presence of registered pharmacist only. If One Nation-One Pharmacist registration is approved then pharmacists can chip in their services anywhere and anytime as many a time there is a shortfall existing in pharmacy outlets for qualified hands, he said. Even the profession of a pharmacy faculty can be broadened if opportunities to  work in pharmacy outlets or an hospitals as counsellors to guide the patient regarding dosages and treatment.  The professional service of a pharmacist even as a faculty can stall self medication which is rampant in the country. Their broadened expertise can be utilised during their guidance to  student community . Aspects of drug to drug interactions and drug-food interactions are critical information that can be shared. This is where One Nation-One Pharmacist registration to bolster recognition of professionals, said Prof. Raveendra.

Discover the top pharmaceutical companies in India listed on the NSE, sorted from highest to lowest by market cap Pharmaceutical companies play a pivotal role in safeguarding public health and well-being. Their significance lies in their pursuit of groundbreaking research, innovation, and the development of life-saving medications. In this blog, we have compiled a list of the top pharma companies in India as listed on the NSE (National Stock Exchange of India). Top 10 pharma companies in India by market cap Below, we have sorted India’s top 10 pharma companies listed on the NSE according to their market caps, from highest to lowest. Note: All market cap data below is sourced from NSE India as of April 24, 2024. Rank Company Name Market Cap (Rs. Cr) Headquarter #1 Sun Pharma 3,65,178.78 Mumbai, Maharashtra #2 Cipla 1,13,915.46 Mumbai, Maharashtra #3 Divi’s Labs 1,05,921.96 Hyderabad, Telangana #4 Dr Reddy’s Labs 1,04,611.73 Hyderabad, Telangana #5 Zydus Life 96,497.84 Ahmedabad, Gujarat #6 Mankind Pharma 95,139.75 Delhi #7 Torrent Pharma 91,312.58 Ahmedabad, Gujarat #8 Lupin 74,617.69 Mumbai, Maharashtra #9 Aurobindo Pharma 67,441.53 Hyderabad, Telangana #10 Alkem Lab 58,431.42 Mumbai, Maharashtra Sun Pharma Managing Director: Dilip Shanghvi Net Sales (Cr.): 20,812.14 Sun Pharmaceutical Industries Limited is the largest pharmaceutical company in India and the sixth-largest generic pharmaceutical manufacturer in the world. It produces and sells pharmaceutical formulations and active pharmaceutical ingredients to over 100 countries worldwide. Recently, Sun Pharmaceutical acquired 100 percent of Libra Merger Ltd, an Israeli company. Cipla Managing Director: Dilip Shanghvi Net Sales (Cr.): 20,812.14 Sun Pharmaceutical Industries Limited is the largest pharmaceutical company in India and the sixth-largest generic pharmaceutical manufacturer in the world. It produces and sells pharmaceutical formulations and active pharmaceutical ingredients to over 100 countries worldwide. Recently, Sun Pharmaceutical acquired 100 percent of Libra Merger Ltd, an Israeli company. Divi’s Labs CEO: Dr. Kiran Divi Net Sales (Cr.): 7,625.30 Divi’s Laboratories Limited specializes in producing active pharmaceutical ingredients and intermediates. The company is engaged in the manufacturing and custom synthesis of generic APIs and intermediates. Zydus Life Managing Director: Sharvil P. Patel Net Sales (Cr.): 8,731.60 Founded in 1952 by Ramanbhai B. Patel and A Modi, Zydus Lifesciences Limited was known as Cadila Healthcare Limited. Today, Zydus Life is predominantly involved in the production of generic drugs. Mankind Pharma CEO: Sheetal Arora Net Sales (Cr.): 8,127.15 Incorporated in 1995, Mankind Pharma specialises in various therapeutic areas, offering products from antibiotics to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications. At the end of 2023, Mankind made an additional investment of £1 million in Actimed Therapeutics, showing a dedication to advancing treatments for cancer cachexia, amyotrophic lateral sclerosis, and multiple muscle wasting issues.  Torrent Pharma Chairman: Samir Mehta Net Sales (Cr.): 7,695.20 The Torrent Group owns Torrent Pharmaceuticals Ltd. Initially promoted by UN Mehta as Trinity Laboratories Ltd., it was later renamed Torrent Pharmaceuticals Ltd. Through strategic acquisitions and diversifications, Torrent Pharma has joined the ranks of the top pharmaceutical companies in India. Lupin CEO: Vinita D Gupta Net Sales (Cr.): 11,258.83 Lupin Limited is globally recognized as one of the largest generic pharmaceutical companies and India’s fifth-largest pharmaceutical company by revenue. Lupin’s key focus areas encompass pediatrics, cardiovascular, anti-infectives, diabetology, asthma, and anti-tuberculosis medications. Aurobindo Pharma CEO: Dr Sanjay Chaturvedi Net Sales (Cr.): 12,792.28 Aurobindo Pharma Limited specializes in producing generic pharmaceuticals and active pharmaceutical ingredients. Founded by Penaka Venkata Ramprasad Reddy and Kambam Nithyananda Reddy in 1986, the company has established itself as one of India’s top pharmaceutical companies. Notably, a subsidiary of the company recently received the USFDA’s (United States Food and Drug Administration) approval for the Posaconazole Injection to prevent severe fungal infections.  Alkem Lab CEO: Dr. Vikas Gupta Net Sales (Cr.): 9,054.55 Alkem Laboratories Limited focuses on manufacturing and selling pharmaceutical generics, formulations, and nutraceuticals. It has a global presence in addition to its strong presence in the Indian market. FAQs Which are the top 5 pharmaceutical companies in the world by market cap? Going by market cap, here are the top 5 pharmaceutical companies in the world as of April 29, 2024: Eli Lilly: Market cap $697.39 billion Novo Nordisk: Market cap $568.92 billion Johnson & Johnson: Market cap $352.16 billion Merck: Market cap $332.33 billion AbbVie: Market cap $282.63 billion   What is the growth rate of the pharmaceutical industry in India? The Indian Pharmaceutical industry is ranked third in pharmaceutical production by volume, having grown at a CAGR of 9.43 percent over the past nine years. According to IBEF, the industry is expected to grow to $65 billion by 2024 and $130 billion by 2030.